Browse > Article
http://dx.doi.org/10.5230/jgc.2018.18.e37

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study  

Gockel, Ines (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Jansen-Winkeln, Boris (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Haase, Linda (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Rhode, Philipp (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Mehdorn, Matthias (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Niebisch, Stefan (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Moulla, Yusef (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Lyros, Orestis (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Lordick, Florian (University Cancer Center Leipzig, University Hospital of Leipzig)
Schierle, Katrin (Institute of Pathology, University Hospital of Leipzig)
Wittekind, Christian (Institute of Pathology, University Hospital of Leipzig)
Thieme, Rene (Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig)
Publication Information
Journal of Gastric Cancer / v.18, no.4, 2018 , pp. 379-391 More about this Journal
Abstract
Purpose: Gastric cancer (GC) patients with peritoneal metastasis (PM) have poor prognosis. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with systemic chemotherapy is a novel treatment option for patients in stage IV of the disease. Materials and Methods: Between November 2015 and June 2018, prospective data collection was performed in 24 patients with GC and PM (median age, 57; range, 44-75 years). These patients underwent 46 PIPAC procedures with a median number of 2 interventions per patient (range, 1-6). A laparoscopic access was used and a combined therapy of cisplatin and doxorubicin aerosol was administered. Results: The median peritoneal carcinomatosis index before the 1st PIPAC was 14 (range, 2-36), and the median ascites volume in patients before the 1st PIPAC was 100 mL (range, 0-6 mL, 300 mL). Eleven patients, who received 2 or more PIPAC procedures, had decreased and stable volumes of ascites, while only 3 patients displayed increasing volume of ascites. The median overall survival was 121 days (range, 66-625 days) after the 1st PIPAC procedure, while 8 patients who received more than 3 PIPAC procedures had a median survival of 450 days (range, 206-481 days) (P=0.0376). Conclusions: Our data show that PIPAC is safe and well tolerated, and that the production of ascites can be controlled by PIPAC in GC patients. Patients, who received 2 or more PIPAC procedures, reported a stable overall quality of life. Further studies are required to document the significance of PIPAC as a palliative multimodal therapy.
Keywords
Gastric cancer; Peritoneal metastasis; PIPAC; Palliative chemotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.   DOI
2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403.   DOI
3 Geng X, Liu H, Lin T, Hu Y, Chen H, Zhao L, et al. Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score-matched analysis. Cancer Med 2016;5:2781-2791.   DOI
4 Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A, et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 2011;20:e38-e54.   DOI
5 Brandl A, Pachmayr E, Gul-Klein S, Alberto M, Thuss-Patience P, Rau B. Surgical treatment of peritoneal metastases of gastric cancer. Chirurg 2018;89:669-677.   DOI
6 Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-592.   DOI
7 Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 2009;100:311-316.   DOI
8 Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010:CD004064.
9 Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221.   DOI
10 Jansen-Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, et al. Perioperative safety of intraperitoneal aerosol chemotherapy: analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures. Chirurg 2018. doi: 10.1007/s00104-018-0667-5 [In press].
11 Nowacki M, Alyami M, Villeneuve L, Mercier F, Hubner M, Willaert W, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol 2018;44:991-996.   DOI
12 Hubner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N. Pressurized intraperitoneal aerosol chemotherapy - practical aspects. Eur J Surg Oncol 2017;43:1102-1109.   DOI
13 Coccolini F, Ansaloni L, Manfredi R, Campanati L, Poiasina E, Bertoli P, et al. Peritoneal adhesion index (PAI): proposal of a score for the “ignored iceberg” of medicine and surgery. World J Emerg Surg 2013;8:6.   DOI
14 Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, eds. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
15 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-374.
16 Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3.   DOI
17 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.   DOI
18 Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol 2017;28:1767-1775.   DOI
19 Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2014;17:213-225.   DOI
20 Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, et al. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer 2018;18:120.   DOI
21 Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hubner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017;104:669-678.   DOI
22 Odendahl K, Solass W, Demtroder C, Giger-Pabst U, Zieren J, Tempfer C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol 2015;41:1379-1385.   DOI
23 Goetze TO, Al-Batran SE, Pabst U, Reymond M, Tempfer C, Bechstein WO, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper GI-adenocarcinomas with peritoneal seeding - a phase II/III trial of the AIO/CAOGI/ACO. Pleura Peritoneum 2018;3.
24 Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol 2017;43:2178-2183.   DOI
25 Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 2016;14:128.   DOI
26 Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 2016;20:367-373.   DOI
27 Giger-Pabst U, Solass W, Strumberg D, Zieren J, Reymond M. Erste klinische ergebnisse der "pressurized intraperitoneal aerosol chemotherapy" (PIPAC) bei patienten mit magenkarzinom und fortgeschrittener peritonealkarzinose. Z Gastroenterol 2013;51:K364.
28 Higaki E, Yanagi S, Gotohda N, Kinoshita T, Kuwata T, Nagino M, et al. Intraoperative peritoneal lavage cytology offers prognostic significance for gastric cancer patients with curative resection. Cancer Sci 2017;108:978-986.   DOI